Sex hormones and acne

dc.contributor.authorJu, Qiang
dc.contributor.authorTao, Tao
dc.contributor.authorHu, Tingting
dc.contributor.authorKaradağ, Ayşe Serap
dc.contributor.authorAl-Khuzaei, Safaa
dc.contributor.authorChen, WenChieh
dc.date.accessioned2025-05-10T19:48:55Z
dc.date.issued2017
dc.departmentİMÜ, Fakülteler, Dahili Tıp Bilimleri Bölümü
dc.description.abstractThe skin is an endocrine organ with the expression of metabolizing enzymes and hormone receptors for diverse hormones. The sebaceous gland is the main site of hormone biosynthesis, especially for androgens, and acne is the classical androgen-mediated dermatosis. In sebocytes, conversion of 17-hydroxyprogesterone directly to dihydrotestosterone bypassing testosterone has been demonstrated, while type II 17 beta-hydroxysteroid dehydrogenase can inactivate the action of testosterone and dihydrotestosterone. The androgen receptor-dependent genomic effect of dihydrotestosterone on sebocytes is confirmed. Further evidence supports the PI3 K/Akt/FoxO1/mTOR signaling in the involvement of the interplay between androgens, insulin, insulin-like growth factor, and hyperglycemic diet in acne. Androgens not only regulate embryology and lipogenesis/sebum synthesis in sebocytes but also influence inflammation in acne. Genetic studies indicate that regulation of the androgen receptor is an important factor in severe acne. Further studies are required to understand the effect of estrogen and progesterone on sebaceous gland and comedogenesis, considering the change of acne in pregnancy and postmenopausal acne. Special attention should be paid to nonobese patients with polycystic ovarian syndrome and hyperandrogenism-insulin resistance-acanthosis nigricans syndrome. In spite of extensive gynecologic experience in the use of combined oral contraceptives for acne, evidence based on dermatologic observation should be intensified. (C) 2017 Elsevier Inc. All rights reserved.
dc.identifier.doi10.1016/j.clindermatol.2016.10.004
dc.identifier.endpage137
dc.identifier.issn0738-081X
dc.identifier.issn1879-1131
dc.identifier.issue2
dc.identifier.pmid28274349
dc.identifier.scopus2-s2.0-85014433759
dc.identifier.scopusqualityQ1
dc.identifier.startpage130
dc.identifier.urihttps://doi.org/10.1016/j.clindermatol.2016.10.004
dc.identifier.urihttps://hdl.handle.net/20.500.14730/11870
dc.identifier.volume35
dc.identifier.wosWOS:000397480100003
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofClinics in Dermatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectCongenital Adrenal-Hyperplasia
dc.subjectGrowth-Factor-I
dc.subjectPolycystic-Ovary-Syndrome
dc.subjectAcute Regulatory Protein
dc.subjectBody-Mass Index
dc.subjectOral-Contraceptives
dc.subjectSteroidogenic Enzymes
dc.subjectAdolescent Acne
dc.subjectModerate Acne
dc.subjectRisk-Factors
dc.titleSex hormones and acne
dc.typeArticle

Dosyalar